Web-based Supplementary Materials
|
|
- Cecil Blair
- 8 years ago
- Views:
Transcription
1 Web-based Supplementary Materials Continual Reassessment Method for Partial Ordering by Nolan A. Wages, Mark R. Conaway, and John O Quigley Web Appendix A: Further details for matrix orders In this section, we provide some further details about the simulation results presented in Section 4.3. Specifically, Table 1 reports the distribution of the percentage of MTD recommendation across each dose combination, whereas Table 2 provides the distribution of allocation across each dose. Through examination of these tables, we can see that the method is treating a large percentage of patients at and around the MTD combinations. In fact, even in cases when POCRM performs less well, the method is recommending doses around the MTD. For instance, in scenario 5, the MTD combinations are only recommended at the conclusion of 38% of the simulated trials. However, doses with true toxicity probabilities between the target, 0.40, and 0.48 are recommended at the end of 86% of the simulated trials. Furthermore, 63% of enrolled patients were treated at doses with true DLT probabilities between 0.40 and Similarly, in scenario 6 the percentage of correct MTD recommendation is 45%, yet 88% of the simualted trials resulted in a dose with a true probability between 0.40 and 0.49 being selected. Moreover, 75% of enrolled patients were treated at doses with probabilities between these two values. 1
2 Table 1: Percent of MTD recommendation based on 2000 simulated trials. Dose Drug A Level Drug B Table 2: Percent of dose allocation based on 2000 simulated trials. Dose Drug A Level Drug B
3 Table 3: Simulation results for POCRM for 5 5 and 6 6 matrix orders Scenario % recommendation % of toxicities % treated at MTD Web Appendix B: Higher orders In this section, we present some simulation results similar to those provided in Section 4.3 of the manuscript in order to illustrate the performance of the proposed design for some higher order matrices (i.e. 5 5 and 6 6). Table 6 lists the true probability of toxicity for each of these scenarios, with the target MTD combination indicated in bold type. In scenarios 1 through 3, there are 25 treatment combinations and in scenarios 4 through 6, there are 36 treatment combinations. We again began by choosing the three simple dose-toxicity orders given in Section 3.3 of the manuscript according to the diagonals of the matrix of treatments Figure 1. Under all scenarios, 2000 trials were simulated for a fixed sample size of n = 50 patients. The target toxicity rate is given in bold type in Table 6 and we utilize a uniform prior distribution, p (m), on the ordering. We generated skeletons according to the approach of Lee and Cheung (2009). Table 3 reports the percentage of correct MTD recommendation, the percentage of observed toxicities and the percentage of patients treated at the MTD for the POCRM. Overall, the simulation results indicate that, in terms of identifying the MTD, the performance of the POCRM is satisfactory for higher orders. The method is recommending and treating patients at the MTD in a large percentage of trials. Furthermore, the simulation results again support the idea that the correct ordering does not need to be one of those chosen for investigation in order for the method to perform well.
4 Table 4: Toxicity scenarios for 5 5 and 6 6 matrix orders Doses
5 Table 5: Percent of MTD recommendation based on 2000 simulated trials. Doses
6 Table 6: Percent of dose allocation based on 2000 simulated trials. Doses
7 Web Appendix C: Alternative Approach This section investigates an alternative approach that accounts for model uncertainty by considering multiple models (orderings) when recommending a dose. As in the manuscript, the key idea for this method is that each of the possible simple orderings consistent with the partial order can be thought of as a model. We assume that there are M possible orderings of the toxicity probabilities for the dose levels that are all being considered. Instead of selecting the ordering with the greatest posterior density and reducing the problem to a standard phase I trial, this approach estimates the dose to recommend to the next entered patient for each distinct ordering and uses the dose that is most agreed upon across all possible orders. That is, it works with the cumulative probabilities for some MTD given the set of models. Consider the simple example where there are four possible orderings. Suppose after j patients have been enrolled, π(1 Ω j ) = π(2 Ω j ) = π(3 Ω j ) = 0.2 recommends d 3 and π(4 Ω j ) = 0.4 recommends d 4. According to POCRM, dose level d 4 will be recommended to the next patient because π(4 Ω j ) is the maximum of all the weights, disregarding the fact that the most agreed upon dose is d 3. This approach measures the cumulative probability and selects the dose that is most agreed upon across all possible orderings. For the simple example described above, the proposed method will choose d 3 instead of d 4 as the dose to be given to the next patient. In the method, the cumulative probability for each d i is the sum of the posterior model probabilities across all orderings which indicate that the recommended dose is d i. Then, we choose the dose level that has the highest cumulative probability. This method for finding the maximum tolerated dose takes into account all the possible orderings and does not limit itself to one particular ordering. To illustrate this alternative approach, consider the example given in Section 2.1 involving k = 6 discrete treatment combinations, d 1,..., d 6. The partial order associated with this trial has associated with it five possible simple orders. Under all scenarios, 2000 trials were simulated for a sample of n = 25 patients. The target toxicity rate is θ = 1/5 and we incorporated a
8 Table 7: Percentage of MTD recommendation %tox R CRM POCRM Alternative approach R CRM POCRM Alternative approach R CRM POCRM Alternative approach R CRM POCRM Alternative approach R CRM POCRM Alternative approach uniform prior distribution, p (m). Once again, the probability of dose-limiting toxic response is modeled via the power parameter model with the skeletons generated via the method of Lee and Cheung (2009). Table 7 indicates that the simulation results of the cumulative probability approach are competitive with that of POCRM, making it a practical alternative as a multipleagent trial design. However, this only gives a snapshot comparison to their method because of the few toxicity scenarios considered.
Bayesian Model Averaging Continual Reassessment Method BMA-CRM. Guosheng Yin and Ying Yuan. August 26, 2009
Bayesian Model Averaging Continual Reassessment Method BMA-CRM Guosheng Yin and Ying Yuan August 26, 2009 This document provides the statistical background for the Bayesian model averaging continual reassessment
More informationBayesian Model Averaging CRM in Phase I Clinical Trials
M.D. Anderson Cancer Center 1 Bayesian Model Averaging CRM in Phase I Clinical Trials Department of Biostatistics U. T. M. D. Anderson Cancer Center Houston, TX Joint work with Guosheng Yin M.D. Anderson
More informationBayesian Adaptive Designs for Early-Phase Oncology Trials
The University of Hong Kong 1 Bayesian Adaptive Designs for Early-Phase Oncology Trials Associate Professor Department of Statistics & Actuarial Science The University of Hong Kong The University of Hong
More informationA Simple Approach For Incorporating Multiple Toxicity Thresholds In Phase I Trials
A Simple Approach For Incorporating Multiple Toxicity Thresholds In Phase I Trials Jieling Miao and Shing M. Lee Columbia University, Department of Biostatistics May 20, 2015 Jieling Miao (Columbia University)
More informationSpecification of the Bayesian CRM: Model and Sample Size. Ken Cheung Department of Biostatistics, Columbia University
Specification of the Bayesian CRM: Model and Sample Size Ken Cheung Department of Biostatistics, Columbia University Phase I Dose Finding Consider a set of K doses with labels d 1, d 2,, d K Study objective:
More informationContinual Reassessment Method
Continual Reassessment Method Adrian Mander MRC Biostatistics Unit Hub for Trials Methodology Research, Cambridge Sep 2011 Adrian Mander Sep 2011 1/17 Outline Introduction to oncology phase I trials Describe
More informationAn introduction to Phase I dual-agent dose escalation trials
An introduction to Phase I dual-agent dose escalation trials Michael Sweeting MRC Biostatistics Unit, Cambridge 13th March 2013 Outline Introduction to phase I trials Aims, objectives and key elements.
More informationAssessing the Effect of Practical Considerations when using the CRM in Dose Finding Studies
Assessing the Effect of Practical s when using the CRM in Dose Finding Studies Caroline Sprecher, University of North Carolina-Chapel Hill Rolando Acosta Nuñez, University of Puerto Rico-Humacao Tyler
More informationTHE RAPID ENROLLMENT DESIGN FOR PHASE I CLINICIAL TRIALS
THE RAPID ENROLLMENT DESIGN FOR PHASE I CLINICIAL TRIALS Anastasia Ivanova 1,2 and Yunfei Wang 1, 1 University of North Carolina Chapel Hill and 2 Lineberger Comprehensive Cancer Center (LCCC) aivanova@bios.unc.edu
More informationAdaptive Design for Intra Patient Dose Escalation in Phase I Trials in Oncology
Adaptive Design for Intra Patient Dose Escalation in Phase I Trials in Oncology Jeremy M.G. Taylor Laura L. Fernandes University of Michigan, Ann Arbor 19th August, 2011 J.M.G. Taylor, L.L. Fernandes Adaptive
More informationADDPLAN DF: Designing More Accurate Dose Escalation Studies in Exploratory Drug Development. An ICON White Paper
ADDPLAN DF: Designing More Accurate Dose Escalation Studies in Exploratory Drug Development An ICON White Paper Executive Summary The determination of the maximum tolerated dose (MTD) level is a critical
More informationTITE-CRM Phase I Clinical Trials: Implementation Using SAS
TITE-CRM Phase I Clinical Trials: Implementation Using SAS University of Michigan Comprehensive Cancer Center Biostatistics Unit Revised: December 2008 Contents 1 Introduction to the TITE-CRM 1 1.1 Phase
More informationPackage CRM. R topics documented: February 19, 2015
Package CRM February 19, 2015 Title Continual Reassessment Method (CRM) for Phase I Clinical Trials Version 1.1.1 Date 2012-2-29 Depends R (>= 2.10.0) Author Qianxing Mo Maintainer Qianxing Mo
More informationExtending the TITE CRM to Multiple Outcomes with Application to a Phase 1 Clinical Trial in Canine Hemangiosarcoma
Extending the TITE CRM to Multiple Outcomes with Application to a Phase 1 Clinical Trial in Canine Hemangiosarcoma Joseph S. Koopmeiners 1,3 and Jaime Modiano 2,3 1 Division of Biostatistics, University
More informationPackage bcrm. September 24, 2015
Type Package Package bcrm September 24, 2015 Title Bayesian Continual Reassessment Method for Phase I Dose-Escalation Trials Version 0.4.5 Date 2015-09-23 Author Michael Sweeting Maintainer Michael Sweeting
More informationBayesian Phase I/II clinical trials in Oncology
Bayesian Phase I/II clinical trials in Oncology Pierre Mancini, Sandrine Micallef, Pierre Colin Séminaire JEM-SFES - 26 Janvier 2012 Outline Oncology phase I trials Limitations of traditional phase I designs
More informationJournal of Statistical Software
JSS Journal of Statistical Software August 213, Volume 54, Issue 13. http://www.jstatsoft.org/ bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials Michael Sweeting MRC
More informationPractical considerations in designing a phase I Time to Event Continual Reassessment Method (TiTE CRM) trial in a grant funded CTU
Practical considerations in designing a phase I Time to Event Continual Reassessment Method (TiTE CRM) trial in a grant funded CTU Eleni Frangou 1, Jane Holmes 1, Sharon Love 1, Lang o Odondi 1,2, Claire
More informationBayesian adaptive designs, with particular reference to dose finding methods in oncology
IV BIAS Annual Congress - Padova 27/09/2012 Advanced Methods in Clinical Trials: surrogate endpoints and adaptive designs Bayesian adaptive designs, with particular reference to dose finding methods in
More informationCLINICAL TRIALS: Part 2 of 2
CLINICAL TRIALS: Part 2 of 2 Lance K. Heilbrun, Ph.D., M.P.H. Professor of Medicine and Oncology Division of Hematology and Oncology Wayne State University School of Medicine Assistant Director, Biostatistics
More informationThe Trials and Tribulations of the CRM: the DFO Experience
The Trials and Tribulations of the CRM: the DFO Experience Yuko Y. Palesch, PhD Professor and Director, Division of Biostatistics and Epidemiology Department of Medicine. Medical University of South Carolina
More informationThe CRM for ordinal and multivariate outcomes. Elizabeth Garrett-Mayer, PhD Emily Van Meter
The CRM for ordinal and multivariate outcomes Elizabeth Garrett-Mayer, PhD Emily Van Meter Hollings Cancer Center Medical University of South Carolina Outline Part 1: Ordinal toxicity model Part 2: Efficacy
More informationWeb-based Supplementary Materials for Bayesian Effect Estimation. Accounting for Adjustment Uncertainty by Chi Wang, Giovanni
1 Web-based Supplementary Materials for Bayesian Effect Estimation Accounting for Adjustment Uncertainty by Chi Wang, Giovanni Parmigiani, and Francesca Dominici In Web Appendix A, we provide detailed
More informationRobust EM Continual Reassessment Method in Oncology Dose Finding
Robust EM Continual Reassessment Methon Oncology Dose Finding Ying YUAN and Guosheng YIN The continual reassessment method (CRM) is a commonly used dose-finding design for phase I clinical trials. Practical
More informationBy Ying Yuan 1 and Guosheng Yin 2 University of Texas and University of Hong Kong
The Annals of Applied Statistics 2011, Vol. 5, No. 2A, 924 942 DOI: 10.1214/10-AOAS433 c Institute of Mathematical Statistics, 2011 BAYESIAN PHASE I/II ADAPTIVELY RANDOMIZED ONCOLOGY TRIALS WITH COMBINED
More informationLikelihood Approaches for Trial Designs in Early Phase Oncology
Likelihood Approaches for Trial Designs in Early Phase Oncology Clinical Trials Elizabeth Garrett-Mayer, PhD Cody Chiuzan, PhD Hollings Cancer Center Department of Public Health Sciences Medical University
More informationEstablish the Maximum Tolerated Dose in Phase-I Trials using 3+3 Method
Paper SP04 Establish the Maximum Tolerated Dose in Phase-I Trials using 3+3 Method Anup Pillai, Cytel, Pune, India ABSTRACT The main goal of Phase-I cancer clinical trials is to find the maximum tolerated
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationDefinition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents
Definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents Department Hospital Town Country Christophe Le Tourneau Medical Oncology Institut Curie Paris France
More informationNewsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationPractical Considerations for Adaptive Trial Design and Implementation
Practical Considerations for Adaptive Trial Design and Implementation EDITED BY WEILI HE, JOSE C. PINHEIRO, AND OLGA M. KUZNETSOVA Springer, New York Statistics for Biology and Health 2014 Chapter 12 Implementation
More informationAnalysis of Bayesian Dynamic Linear Models
Analysis of Bayesian Dynamic Linear Models Emily M. Casleton December 17, 2010 1 Introduction The main purpose of this project is to explore the Bayesian analysis of Dynamic Linear Models (DLMs). The main
More information5. Orthogonal matrices
L Vandenberghe EE133A (Spring 2016) 5 Orthogonal matrices matrices with orthonormal columns orthogonal matrices tall matrices with orthonormal columns complex matrices with orthonormal columns 5-1 Orthonormal
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationF Matrix Calculus F 1
F Matrix Calculus F 1 Appendix F: MATRIX CALCULUS TABLE OF CONTENTS Page F1 Introduction F 3 F2 The Derivatives of Vector Functions F 3 F21 Derivative of Vector with Respect to Vector F 3 F22 Derivative
More informationSome probability and statistics
Appendix A Some probability and statistics A Probabilities, random variables and their distribution We summarize a few of the basic concepts of random variables, usually denoted by capital letters, X,Y,
More informationCONDITIONAL, PARTIAL AND RANK CORRELATION FOR THE ELLIPTICAL COPULA; DEPENDENCE MODELLING IN UNCERTAINTY ANALYSIS
CONDITIONAL, PARTIAL AND RANK CORRELATION FOR THE ELLIPTICAL COPULA; DEPENDENCE MODELLING IN UNCERTAINTY ANALYSIS D. Kurowicka, R.M. Cooke Delft University of Technology, Mekelweg 4, 68CD Delft, Netherlands
More informationImportant Probability Distributions OPRE 6301
Important Probability Distributions OPRE 6301 Important Distributions... Certain probability distributions occur with such regularity in real-life applications that they have been given their own names.
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL) An exploratory study to assess the association between healthrelated
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf)
More informationInner Product Spaces
Math 571 Inner Product Spaces 1. Preliminaries An inner product space is a vector space V along with a function, called an inner product which associates each pair of vectors u, v with a scalar u, v, and
More informationUsing the package crmpack: introductory examples
Using the package crmpack: introductory examples Daniel Sabanés Bové Wai Yin Yeung 1th November 215 Package version.1.5 This short vignette shall introduce into the usage of the package crmpack. Hopefully
More informationAccelerated Titration Designs for Phase I Clinical Trials in Oncology
Accelerated Titration Designs for Phase I Clinical Trials in Oncology Richard Simon, Boris Freidlin, Larry Rubinstein, Susan G. Arbuck, Jerry Collins, Michaele C. Christian* Background: Many cancer patients
More informationAnalysis of Load Frequency Control Performance Assessment Criteria
520 IEEE TRANSACTIONS ON POWER SYSTEMS, VOL. 16, NO. 3, AUGUST 2001 Analysis of Load Frequency Control Performance Assessment Criteria George Gross, Fellow, IEEE and Jeong Woo Lee Abstract This paper presents
More informationPROJECT RISK MANAGEMENT
PROJECT RISK MANAGEMENT http://www.tutorialspoint.com/pmp-exams/project_risk_management.htm Copyright tutorialspoint.com Here is a list of sample questions which would help you to understand the pattern
More informationLogistic Regression. Jia Li. Department of Statistics The Pennsylvania State University. Logistic Regression
Logistic Regression Department of Statistics The Pennsylvania State University Email: jiali@stat.psu.edu Logistic Regression Preserve linear classification boundaries. By the Bayes rule: Ĝ(x) = arg max
More informationICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals International Conference on Harmonisation of Technical Requirements
More informationSummary and general discussion
Chapter 7 Summary and general discussion Summary and general discussion In this thesis, treatment of vitamin K antagonist-associated bleed with prothrombin complex concentrate was addressed. In this we
More informationAnalysis of Uncertain Data: Tools for Representation and Processing
Analysis of Uncertain Data: Tools for Representation and Processing Bin Fu binf@cs.cmu.edu Eugene Fink e.fink@cs.cmu.edu Jaime G. Carbonell jgc@cs.cmu.edu Abstract We present initial work on a general-purpose
More informationPubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH
PubH 7470: STATISTICS FOR TRANSLATIONAL & CLINICAL RESEARCH CLINICAL TRIALS: TWO-STAGE PHASE II TRIALS This lecture covers a very special form of phase II clinical trials: two-stage design. A small group
More informationLloyd Spencer Lincoln Re
AN OVERVIEW OF THE PANJER METHOD FOR DERIVING THE AGGREGATE CLAIMS DISTRIBUTION Lloyd Spencer Lincoln Re Harry H. Panjer derives a recursive method for deriving the aggregate distribution of claims in
More informationSequential Designs for Phase I Clinical Trials with Late-Onset Toxicities
BIOMETRICS 56, 11771182 December 2000 Sequential Designs for Phase I Clinical Trials with LateOnset Toxicities Ying Kuen Cheung* and Rick Chappell Department of Statistics and Department of Biostatistics
More informationUptake of adaptive and Bayesian methods in the design of early phase trials within CTUs
Uptake of adaptive and Bayesian methods in the design of early phase trials within CTUs Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom PLEASE DO NOT REPRODUCE
More informationWHITE PAPER: ADAPTIVE CLINICAL TRIALS
WHITE PAPER: ADAPTIVE CLINICAL TRIALS P. Ranganath Nayak, Chief Executive Officer, Cytel Inc. James A. Bolognese, Senior Director, Cytel Consulting The Adaptive Concept The clinical development of drugs
More informationCOMPENSATION PLAN. One Time Payment Fee Paid Commission Sales Agent $5,500 $1,000.00. Partial Payment Fee Paid Commission Sales Agent $1,000 $181.
COMPENSATION PLAN Enrollment Fee: $6,500 Full Payment: $5,500 ($1,000 discount) Partial Payment: $1,000 initial fee Partial Payment Fee: $500 (11 months) Admin Fee: $148 month, starting 13 th month Personal
More informationU.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
More informationTHE NUMBER OF GRAPHS AND A RANDOM GRAPH WITH A GIVEN DEGREE SEQUENCE. Alexander Barvinok
THE NUMBER OF GRAPHS AND A RANDOM GRAPH WITH A GIVEN DEGREE SEQUENCE Alexer Barvinok Papers are available at http://www.math.lsa.umich.edu/ barvinok/papers.html This is a joint work with J.A. Hartigan
More informationMarkov Chain Monte Carlo Simulation Made Simple
Markov Chain Monte Carlo Simulation Made Simple Alastair Smith Department of Politics New York University April2,2003 1 Markov Chain Monte Carlo (MCMC) simualtion is a powerful technique to perform numerical
More informationA Phase 2B company treating Secondary Progressive Multiple Sclerosis. Annual General Meeting - August 2014
A Phase 2B company treating Secondary Progressive Multiple Sclerosis Annual General Meeting - August 2014 Forward Looking Statements This Presentation (and any financial information that may be provided
More informationThe long-term projections of federal revenues and
APPENDIX B Changes in s Long-Term Projections Since July 214 The long-term projections of federal revenues and outlays presented in this report are generally similar to the ones that the Congressional
More informationChapter 3 RANDOM VARIATE GENERATION
Chapter 3 RANDOM VARIATE GENERATION In order to do a Monte Carlo simulation either by hand or by computer, techniques must be developed for generating values of random variables having known distributions.
More informationDRAFT RESEARCH SUPPORT BUILDING AND INFRASTRUCTURE MODERNIZATION RISK MANAGEMENT PLAN. April 2009 SLAC I 050 07010 002
DRAFT RESEARCH SUPPORT BUILDING AND INFRASTRUCTURE MODERNIZATION RISK MANAGEMENT PLAN April 2009 SLAC I 050 07010 002 Risk Management Plan Contents 1.0 INTRODUCTION... 1 1.1 Scope... 1 2.0 MANAGEMENT
More informationGaussian Processes to Speed up Hamiltonian Monte Carlo
Gaussian Processes to Speed up Hamiltonian Monte Carlo Matthieu Lê Murray, Iain http://videolectures.net/mlss09uk_murray_mcmc/ Rasmussen, Carl Edward. "Gaussian processes to speed up hybrid Monte Carlo
More informationwhite paper Adaptive Trial Designs to Advance Oncology Research
white paper Adaptive Trial Designs to Advance Oncology Research ppdi.com January 2013 EXECUTIVE SUMMARY Traditional oncology trials are inefficient, expensive, and suffer from high failure rates. Adaptive
More informationSampling Distributions
Sampling Distributions You have seen probability distributions of various types. The normal distribution is an example of a continuous distribution that is often used for quantitative measures such as
More informationCreate efficiencies and improve customer experience through a purpose built system
Create efficiencies and improve customer experience through a purpose built system Universities are choosing to implement purpose built systems to manage their executive/professional programmes and events.
More information5.3 The Cross Product in R 3
53 The Cross Product in R 3 Definition 531 Let u = [u 1, u 2, u 3 ] and v = [v 1, v 2, v 3 ] Then the vector given by [u 2 v 3 u 3 v 2, u 3 v 1 u 1 v 3, u 1 v 2 u 2 v 1 ] is called the cross product (or
More informationIntroduction to Matrices for Engineers
Introduction to Matrices for Engineers C.T.J. Dodson, School of Mathematics, Manchester Universit 1 What is a Matrix? A matrix is a rectangular arra of elements, usuall numbers, e.g. 1 0-8 4 0-1 1 0 11
More informationFor personal use only
APPENDIX 4D INTERIM FINANCIAL REPORT RESULTS FOR ANNOUNCEMENT TO THE MARKET Appendix 4D item 2.1 Revenue from ordinary activities. Appendix 4D item 2.2 Profit (loss) from ordinary activities after tax
More informationOver the last several years, the Bureau
insurance statistics Health insurance statistics New statistics for health insurance from the National Compensation Survey Integrating compensation programs into the NCS provides new opportunities for
More informationFinancial Planning with Your Retirement Portfolio
Financial Planning with Your Retirement Portfolio Excel files used in this case: retirement.xlsx retirementrisk.xlsx retirementriskgoal.xlsx retirementtiaa.xlsx Today is January 1, 2014. After 35 years
More informationMaximum Likelihood Estimation
Math 541: Statistical Theory II Lecturer: Songfeng Zheng Maximum Likelihood Estimation 1 Maximum Likelihood Estimation Maximum likelihood is a relatively simple method of constructing an estimator for
More informationDose Escalation Methods in Phase I Cancer Clinical Trials
REVIEW Dose Escalation Methods in Phase I Cancer Clinical Trials Christophe Le Tourneau, J. Jack Lee, Lillian L. Siu Phase I clinical trials are an essential step in the development of anticancer drugs.
More informationCITY UNIVERSITY LONDON. BEng Degree in Computer Systems Engineering Part II BSc Degree in Computer Systems Engineering Part III PART 2 EXAMINATION
No: CITY UNIVERSITY LONDON BEng Degree in Computer Systems Engineering Part II BSc Degree in Computer Systems Engineering Part III PART 2 EXAMINATION ENGINEERING MATHEMATICS 2 (resit) EX2005 Date: August
More informationSession 6 Clinical Trial Assessment Phase I Clinical Trial
L1 Session 6 Clinical Trial Assessment Phase I Clinical Trial Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More information[1] Diagonal factorization
8.03 LA.6: Diagonalization and Orthogonal Matrices [ Diagonal factorization [2 Solving systems of first order differential equations [3 Symmetric and Orthonormal Matrices [ Diagonal factorization Recall:
More informationCourse 13: Interactive Exercise Workers Compensation & Lost Wage Example
Course 13: Interactive Exercise Workers Compensation & Lost Wage Example You may use the research software, ERI Salary Assessor, to help you calculate lost wages. This simulation will show you how to find
More informationHow to report the percentage of explained common variance in exploratory factor analysis
UNIVERSITAT ROVIRA I VIRGILI How to report the percentage of explained common variance in exploratory factor analysis Tarragona 2013 Please reference this document as: Lorenzo-Seva, U. (2013). How to report
More informationA Review of the Disaster Recovery Testing Process
To: LASERS Audit Committee; Cindy Rougeou, Executive Director Cc: Maris LeBlanc, Deputy Director; Lance Armstrong, IT Director; Dan Bowden, IT Deputy Director From: Ryan Babin, Audit Director; Blake Lee,
More informationSmall Business Health Care Tax Credit
Small Business Health Care Tax Credit Small Business Health Tax Credit Began in 2010 Helps small businesses and tax-exempt organizations afford the cost of covering their employees Specifically targeted
More information1 Introduction to Matrices
1 Introduction to Matrices In this section, important definitions and results from matrix algebra that are useful in regression analysis are introduced. While all statements below regarding the columns
More informationA Predictive Probability Design Software for Phase II Cancer Clinical Trials Version 1.0.0
A Predictive Probability Design Software for Phase II Cancer Clinical Trials Version 1.0.0 Nan Chen Diane Liu J. Jack Lee University of Texas M.D. Anderson Cancer Center March 23 2010 1. Calculation Method
More informationProbability: Terminology and Examples Class 2, 18.05, Spring 2014 Jeremy Orloff and Jonathan Bloom
Probability: Terminology and Examples Class 2, 18.05, Spring 2014 Jeremy Orloff and Jonathan Bloom 1 Learning Goals 1. Know the definitions of sample space, event and probability function. 2. Be able to
More informationBranch-and-Price Approach to the Vehicle Routing Problem with Time Windows
TECHNISCHE UNIVERSITEIT EINDHOVEN Branch-and-Price Approach to the Vehicle Routing Problem with Time Windows Lloyd A. Fasting May 2014 Supervisors: dr. M. Firat dr.ir. M.A.A. Boon J. van Twist MSc. Contents
More informationHistory of the CD BOCES
Online School Accreditation Plan and Annual Performance Report History of the CD BOCES The Colorado Digital Board of Cooperative Educational Services was formed through a cooperative with the Falcon School
More informationStatistical Machine Learning from Data
Samy Bengio Statistical Machine Learning from Data 1 Statistical Machine Learning from Data Gaussian Mixture Models Samy Bengio IDIAP Research Institute, Martigny, Switzerland, and Ecole Polytechnique
More informationA Profit-Maximizing Production Lot sizing Decision Model with Stochastic Demand
A Profit-Maximizing Production Lot sizing Decision Model with Stochastic Demand Kizito Paul Mubiru Department of Mechanical and Production Engineering Kyambogo University, Uganda Abstract - Demand uncertainty
More informationOnline Appendix Feedback Effects, Asymmetric Trading, and the Limits to Arbitrage
Online Appendix Feedback Effects, Asymmetric Trading, and the Limits to Arbitrage Alex Edmans LBS, NBER, CEPR, and ECGI Itay Goldstein Wharton Wei Jiang Columbia May 8, 05 A Proofs of Propositions and
More informationLecture 9: Introduction to Pattern Analysis
Lecture 9: Introduction to Pattern Analysis g Features, patterns and classifiers g Components of a PR system g An example g Probability definitions g Bayes Theorem g Gaussian densities Features, patterns
More information1 Sufficient statistics
1 Sufficient statistics A statistic is a function T = rx 1, X 2,, X n of the random sample X 1, X 2,, X n. Examples are X n = 1 n s 2 = = X i, 1 n 1 the sample mean X i X n 2, the sample variance T 1 =
More information0.1 Phase Estimation Technique
Phase Estimation In this lecture we will describe Kitaev s phase estimation algorithm, and use it to obtain an alternate derivation of a quantum factoring algorithm We will also use this technique to design
More informationDose-Finding with Two Agents in Phase I Oncology Trials
Biometrics 59, 487 496 September 2003 Dose-Finding with Two Agents in Phase I Oncology Trials Peter F. Thall, 1, Randall E. Millikan, 2 Peter Mueller, 1 and Sang-Joon Lee 1 1 Department of Biostatistics,
More information11th National Convention on Statistics (NCS) EDSA Shangri-La Hotel October 4-5, 2010
11th National Convention on Statistics (NCS) EDSA Shangri-La Hotel October 4-5, 2010 INPUT-OUTPUT MULTIPLIER ANALYSIS FOR MAJOR INDUSTRIES IN THE PHILIPPINES by Madeline B. Dumaua For additional information,
More informationMathematical finance and linear programming (optimization)
Mathematical finance and linear programming (optimization) Geir Dahl September 15, 2009 1 Introduction The purpose of this short note is to explain how linear programming (LP) (=linear optimization) may
More informationMASSACHUSETTS INSTITUTE OF TECHNOLOGY 6.436J/15.085J Fall 2008 Lecture 5 9/17/2008 RANDOM VARIABLES
MASSACHUSETTS INSTITUTE OF TECHNOLOGY 6.436J/15.085J Fall 2008 Lecture 5 9/17/2008 RANDOM VARIABLES Contents 1. Random variables and measurable functions 2. Cumulative distribution functions 3. Discrete
More informationActive centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationThe Bass Model: Marketing Engineering Technical Note 1
The Bass Model: Marketing Engineering Technical Note 1 Table of Contents Introduction Description of the Bass model Generalized Bass model Estimating the Bass model parameters Using Bass Model Estimates
More informationOPTIMAL BINARY SEARCH TREES
OPTIMAL BINARY SEARCH TREES 1. PREPARATION BEFORE LAB DATA STRUCTURES An optimal binary search tree is a binary search tree for which the nodes are arranged on levels such that the tree cost is minimum.
More informationn 2 + 4n + 3. The answer in decimal form (for the Blitz): 0, 75. Solution. (n + 1)(n + 3) = n + 3 2 lim m 2 1
. Calculate the sum of the series Answer: 3 4. n 2 + 4n + 3. The answer in decimal form (for the Blitz):, 75. Solution. n 2 + 4n + 3 = (n + )(n + 3) = (n + 3) (n + ) = 2 (n + )(n + 3) ( 2 n + ) = m ( n
More information